STOCK TITAN

ProPhase Labs to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ProPhase Labs (Nasdaq: PRPH) announced that CEO Ted Karkus will present a corporate overview during the Access to Giving Virtual Investor Conference from July 13-15, 2021. Karkus's presentation is scheduled for July 15 at 9:30 AM ET, with management available for one-on-one meetings throughout the event. ProPhase Labs specializes in medical science and technology, including diagnostic testing for COVID-19 and other respiratory illnesses, with results provided in under 24 hours. For more details, visit www.ProPhaseLabs.com.

Positive
  • None.
Negative
  • None.

GARDEN CITY, NY, July 12, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announced that Chief Executive Officer Ted Karkus will present a corporate overview at the Access to Giving Virtual Investor Conference being held on July 13 - 15, 2021.

Mr. Karkus will deliver his corporate presentation on July 15 at 9:30am ET. Management will be available for one-on-one meetings to be held throughout the conference.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com.

Investors can register here.

About ProPhase Labs

ProPhase Labs, Inc. (Nasdaq: PRPH) is a diversified medical science and technology company. The Company’s subsidiary, ProPhase Diagnostics, offers a broad array of clinical diagnostic insights and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients with SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Our methodology also has the capability to identify the possibility of mutations. Critical to COVID testing, results are provided in under 24 hours. ProPhase also offers PCR (polymerase chain reaction) testing for Influenzas A and B and RSV. ProPhase Diagnostics now offers antigen and antibody/immunity tests in partnership with scientists to broaden its COVID-19 testing beyond RT-PCR testing. ProPhase Labs researches, develops, manufactures, distributes, markets, and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

Contact:
CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com


FAQ

When will ProPhase Labs CEO Ted Karkus present at the Access to Giving Virtual Investor Conference?

Ted Karkus will present on July 15, 2021, at 9:30 AM ET.

What is the purpose of ProPhase Labs' presentation at the conference?

The presentation aims to provide a corporate overview and connect with investors.

How can investors schedule a one-on-one meeting with ProPhase Labs management?

Investors can schedule a one-on-one meeting by emailing angie.goertz@issuerdirect.com.

What services does ProPhase Diagnostics offer related to COVID-19?

ProPhase Diagnostics provides COVID-19 testing via saliva and nasal swabs, with results in under 24 hours.

Where can I find more information about ProPhase Labs?

More information can be found at www.ProPhaseLabs.com.

ProPhase Labs, Inc.

NASDAQ:PRPH

PRPH Rankings

PRPH Latest News

PRPH Stock Data

14.72M
20.54M
14.34%
7.64%
0.81%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
NEW YORK